Skip to main content

Sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine Side Effects

Applies to sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine: intramuscular suspension.

General

The most commonly reported side effects included injection site pain, fatigue, headache, and myalgia.[Ref]

Cardiovascular

Postmarketing reports: Myocarditis, pericarditis[Ref]

Dermatologic

Postmarketing reports: Angioedema, erythema multiforme, pruritus, skin rash, urticaria[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 13.7%)

Common (1% to 10%): Vomiting

Uncommon (0.1% to 1%): Nausea[Ref]

Hematologic

Uncommon (0.1% to 1%): Lymphadenopathy[Ref]

Hypersensitivity

Postmarketing reports: Anaphylaxis, severe allergic reactions[Ref]

Local

Very common (10% or more): Injection site pain (up to 79.4%)

Common (1% to 10%): Injection site redness, injection site swelling[Ref]

Metabolic

Uncommon (0.1% to 1%): Decreased appetite[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (up to 33.7%), new/worsened muscle pain (up to 31.4%), arthralgia (up to 23.5%), new/worsened joint pain (up to 16.7%)

Common (1% to 10%): Extremity pain (arm)

Frequency not reported: Joint pain, muscle pain[Ref]

Nervous system

Very common (10% or more): Headache (up to 47.6%)

Frequency not reported: Bell's palsy, facial paralysis

Postmarketing reports: Dizziness, hypoesthesia, paresthesia[Ref]

Bell's palsy was mild to moderate in severity, began 3 to 48 days after the last dose, included facial paralysis and facial paresis, and typically lasted 3 to 68 days. This side effect was reported in 4 participants who received the vaccine and 2 patients who received a placebo, but a causal relationship to the vaccine could not be made.[Ref]

Other

Very common (10% or more): Fatigue (up to 64.3%), use of antipyretic/pain medication (up to 46.7%), chills (up to 31.6%)

Common (1% to 10%): Fever (at least 38C)

Uncommon (0.1% to 1%): Malaise[Ref]

More about sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine

Related treatment guides

References

1. Product Information. Comirnaty Original and Omicron BA 4-BA 5 (SARS-CoV-2 (famtozinameran and tozinameran 12y+) bivalent booster). Pfizer Canada Inc. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer